{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:41:57Z","timestamp":1781804517337,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC011038"],"award-info":[{"award-number":["ZIA BC011038"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Z01 BC011089"],"award-info":[{"award-number":["Z01 BC011089"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIC BC011044"],"award-info":[{"award-number":["ZIC BC011044"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC011028"],"award-info":[{"award-number":["ZIA BC011028"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012728","name":"Frederick National Laboratory for Cancer Research","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100012728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.urology.2020.11.025","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T22:15:40Z","timestamp":1606169740000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma"],"prefix":"10.1016","volume":"149","author":[{"given":"Martin","family":"Lang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy D.","family":"Vocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ricketts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Metwalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Linehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2020.11.025_bib0001","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1101\/gr.131110.111","article-title":"Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics","volume":"22","author":"Linehan","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.urology.2020.11.025_bib0002","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1541-7786.MCR-13-0111","article-title":"A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma","volume":"11","author":"Farley","year":"2013","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.urology.2020.11.025_bib0003","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Cancer Genome Atlas Research","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2020.11.025_bib0004","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.urology.2020.11.025_bib0005","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1073\/pnas.051633798","article-title":"Inherited susceptibility to uterine leiomyomas and renal cell cancer","volume":"98","author":"Launonen","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urology.2020.11.025_bib0006","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/hmg\/5.9.1333","article-title":"The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses anovel gene PRCC to the TFE3 transcription factor gene","volume":"5","author":"Sidhar","year":"1996","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.urology.2020.11.025_bib0007","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature10539","article-title":"A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma","volume":"480","author":"Bertolotto","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.urology.2020.11.025_bib0008","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.urology.2020.11.025_bib0009","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10630","article-title":"A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma","volume":"480","author":"Yokoyama","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.urology.2020.11.025_bib0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.urology.2020.11.025_bib0011","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/pcmr.12047","article-title":"Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history","volume":"26","author":"Ghiorzo","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.urology.2020.11.025_bib0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamadermatol.2015.4356","article-title":"Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations","volume":"152","author":"Potrony","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.urology.2020.11.025_bib0013","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/pcmr.12215","article-title":"MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors","volume":"27","author":"Berwick","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.urology.2020.11.025_bib0014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000443311","article-title":"The microphthalmia-associated transcription factor p.E318K mutation does not play a major role in sporadic renal cell tumors from caucasian patients","volume":"83","author":"Stoehr","year":"2016","journal-title":"Pathobiology"},{"key":"10.1016\/j.urology.2020.11.025_bib0015","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1002\/cncr.30893","article-title":"Advances in the diagnosis of hereditary kidney cancer: initial results of a multigene panel test","volume":"123","author":"Nguyen","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2020.11.025_bib0016","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004754","article-title":"The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris","volume":"7","author":"Martina","year":"2014","journal-title":"Sci Signal"},{"key":"10.1016\/j.urology.2020.11.025_bib0017","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urology.2020.11.025_bib0018","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.semdp.2015.02.003","article-title":"MiT family translocation renal cell carcinoma","volume":"32","author":"Argani","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.urology.2020.11.025_bib0019","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng.3146","article-title":"Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes","volume":"47","author":"Durinck","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.urology.2020.11.025_bib0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/pcmr.12370","article-title":"Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy","volume":"28","author":"Wellbrock","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.urology.2020.11.025_bib0021","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1074\/jbc.M411757200","article-title":"Sumoylation of MITF and its related family members TFE3 and TFEB","volume":"280","author":"Miller","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urology.2020.11.025_bib0022","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/gcc.22476","article-title":"Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276)","volume":"56","author":"Yang","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.urology.2020.11.025_bib0023","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.urolonc.2019.02.015","article-title":"A comparison of outcomes for standard and multiplex partial nephrectomy in a solitary kidney: The National Cancer Institute experience","volume":"37","author":"Baiocco","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2020.11.025_bib0024","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MOU.0b013e32834964ea","article-title":"Repeat partial nephrectomy: surgical, functional and oncological outcomes","volume":"21","author":"Shuch","year":"2011","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urology.2020.11.025_bib0025","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.5858\/arpa.2015-0196-RA","article-title":"MiT family translocation-associated renal cell carcinoma: a contemporary update with emphasis on morphologic, immunophenotypic, and molecular mimics","volume":"139","author":"Magers","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.urology.2020.11.025_bib0026","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11934-018-0829-5","article-title":"Imaging for screening and surveillance of patients with Hereditary Forms of renal cell carcinoma","volume":"19","author":"Freifeld","year":"2018","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2020.11.025_bib0027","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2019.06.015","article-title":"Familial kidney cancer: implications of new syndromes and molecular insights","volume":"76","author":"Carlo","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.11.025_bib0028","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1158\/1078-0432.CCR-13-3036","article-title":"Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes","volume":"20","author":"Malouf","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2020.11.025_bib0029","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/jid.2014.319","article-title":"Pro-survival role of MITF in melanoma","volume":"135","author":"Hartman","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.urology.2020.11.025_bib0030","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.urology.2020.11.025_bib0031","doi-asserted-by":"crossref","first-page":"e15793","DOI":"10.1371\/journal.pone.0015793","article-title":"Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization","volume":"5","author":"Hong","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.urology.2020.11.025_bib0032","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1755-148X.2008.00518.x","article-title":"Gpnmb is a melanoblast-expressed, MITF-dependent gene","volume":"22","author":"Loftus","year":"2009","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.urology.2020.11.025_bib0033","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-05-2018","article-title":"CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma","volume":"12","author":"Tse","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2020.11.025_bib0034","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1200\/JCO.2013.52.5683","article-title":"Phase I\/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer","volume":"32","author":"Bendell","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.11.025_bib0035","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2013.54.8115","article-title":"Phase I\/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma","volume":"32","author":"Ott","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.11.025_bib0036","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.2014.56.2959","article-title":"EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer","volume":"33","author":"Yardley","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.11.025_bib0037","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/cncr.31578","article-title":"The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing","volume":"124","author":"Cajaiba","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2020.11.025_bib0038","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2020.11.025_bib0039","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer Genome Atlas","year":"2013","journal-title":"Nature"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520314047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520314047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:56:35Z","timestamp":1777474595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429520314047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":39,"alternative-id":["S0090429520314047"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2020.11.025","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2020.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}